We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

53 hedge funds and large institutions have $428M invested in Inozyme Pharma in 2020 Q3 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

69.77% more ownership

Funds ownership: 0% → 69.77% (+70%)

Holders
53
Holders Change
+53
Holders Change %
–
% of All Funds
1.07%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
53
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
+$63.8M
2
NMC
NEA Management Company
Maryland
+$60.7M
3
SI
Sofinnova Investments
California
+$50.4M
4
RCM
RA Capital Management
Massachusetts
+$49.8M
5
DM
Deerfield Management
New York
+$28.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$67.5M +$63.8M +2,569,379 New
NMC
2
NEA Management Company
Maryland
$64.3M +$60.7M +2,444,379 New
SI
3
Sofinnova Investments
California
$53.3M +$50.4M +2,028,308 New
RCM
4
RA Capital Management
Massachusetts
$52.7M +$49.8M +2,003,653 New
DM
5
Deerfield Management
New York
$30.2M +$28.6M +1,150,299 New
CA
6
CHI Advisors
New York
$26.5M +$25.1M +1,009,117 New
RSCM
7
Rock Springs Capital Management
Maryland
$23.1M +$21.9M +879,954 New
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$21M +$19.9M +800,000 New
Fidelity Investments
9
Fidelity Investments
Massachusetts
$16M +$15.1M +609,380 New
BlackRock
10
BlackRock
New York
$13.2M +$12.4M +500,934 New
O
11
OrbiMed
New York
$10.5M +$9.95M +400,400 New
Wellington Management Group
12
Wellington Management Group
Massachusetts
$8.01M +$7.57M +304,691 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$7.81M +$7.38M +297,037 New
Citadel Advisors
14
Citadel Advisors
Florida
$6.34M +$5.99M +241,078 New
SFM
15
Sphera Funds Management
Israel
$5.16M +$4.88M +196,411 New
BBA
16
Baker Bros. Advisors
New York
$3.12M +$2.94M +118,500 New
YU
17
Yale University
Connecticut
$2.98M +$2.82M +113,502 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.58M +$2.44M +98,284 New
Northern Trust
19
Northern Trust
Illinois
$2.44M +$2.3M +92,764 New
State Street
20
State Street
Massachusetts
$1.86M +$1.75M +70,585 New
APM
21
Avidity Partners Management
Texas
$1.63M +$1.54M +61,855 New
Charles Schwab
22
Charles Schwab
California
$1.27M +$1.2M +48,334 New
MF
23
Magnetar Financial
Illinois
$633K +$598K +24,075 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$509K +$481K +19,385 New
N
25
Nuveen
North Carolina
$449K +$424K +17,070 New
1
2 3

INZY Hedge Fund Activity: Q3 2020 in Review

53 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2020, worth a combined $428M.

Buyers outnumbered sellers: 53 funds opened new INZY positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $63.8M.

  • 53 institutional investors held Inozyme Pharma (INZY) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $428M of Inozyme Pharma stock for Q3 2020.
  • 53 funds opened new Inozyme Pharma positions in Q3 2020 and 0 closed out, a net change of +53 holders.
  • The largest Inozyme Pharma buyer in Q3 2020 was Novo Holdings A/S, an estimated $63.8M added.

Based on aggregated 13F filings for Q3 2020.